Connection

Jean-Charles Soria to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Aged, 80 and over.
Jean-Charles Soria
Connection Strength
0.254
Aged, 80 and over
  1. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
    View in: PubMed
    Score: 0.022
  2. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
    View in: PubMed
    Score: 0.021
  3. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 11; 86:186-196.
    View in: PubMed
    Score: 0.021
  4. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur J Cancer. 2017 08; 81:142-150.
    View in: PubMed
    Score: 0.020
  5. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
    View in: PubMed
    Score: 0.020
  6. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512.
    View in: PubMed
    Score: 0.020
  7. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017 06; 7(6):586-595.
    View in: PubMed
    Score: 0.020
  8. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
    View in: PubMed
    Score: 0.020
  9. Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers. Am J Clin Oncol. 2009 Feb; 32(1):1-8.
    View in: PubMed
    Score: 0.011
  10. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021 12; 28(12):3297-3315.
    View in: PubMed
    Score: 0.007
  11. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
    View in: PubMed
    Score: 0.006
  12. Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. Eur J Cancer. 2018 07; 98:17-22.
    View in: PubMed
    Score: 0.005
  13. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018 05; 95:68-74.
    View in: PubMed
    Score: 0.005
  14. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
    View in: PubMed
    Score: 0.005
  15. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 03; 91:21-29.
    View in: PubMed
    Score: 0.005
  16. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
    View in: PubMed
    Score: 0.005
  17. Are phase I trials safe for older patients? J Geriatr Oncol. 2018 03; 9(2):87-92.
    View in: PubMed
    Score: 0.005
  18. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
    View in: PubMed
    Score: 0.005
  19. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017 10; 112:10-15.
    View in: PubMed
    Score: 0.005
  20. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
    View in: PubMed
    Score: 0.005
  21. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Invest New Drugs. 2018 02; 36(1):62-74.
    View in: PubMed
    Score: 0.005
  22. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs. 2017 06; 28(5):540-545.
    View in: PubMed
    Score: 0.005
  23. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res. 2017 05 01; 77(9):2222-2230.
    View in: PubMed
    Score: 0.005
  24. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
    View in: PubMed
    Score: 0.005
  25. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer. 2004 Mar 22; 90(6):1222-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.